1. Merck & ASCO: It Is All About Keytruda (Pembrolizumab) http://www.trefis.com/stock/mrk/articles/296707/merck-asco-it-is-all-about-keytruda-pembrolizumab/2015-05-21 by Trefis Team $MRK $RHHBY $BMY

  2. ASCO Will Be Important For Roche http://www.trefis.com/stock/rhhby/articles/296335/asco-will-be-important-for-roche/2015-05-20 by Trefis Team $RHHBY $BMY $MRK

  3. FDA s New Warning About Invokana May Not Matter Much For J&J, Let s Focus On Pipel... http://www.trefis.com/stock/jnj/articles/297072/fdas-new-warning-about-invokana-may-not-matter-much-for-jj-lets-focus-on-pipeline-instead/2015-05-19 by Trefis Team $JNJ $RHHBY $BMY

  4. Bristol-Myers Squibb Pins Its Hopes On Eliquis And Immuno-Oncology http://www.trefis.com/stock/bmy/articles/294395/bristol-myers-squibb-pins-its-hopes-on-eliquis-and-immuno-oncology/2015-05-08 by Trefis Team $BMY $RHHBY $JNJ

  5. Is There A Silver Lining For Pfizer Amid Challenging Conditions? http://www.trefis.com/stock/pfe/articles/293930/is-there-silver-lining-for-pfizer-amid-challenging-conditions/2015-05-05 by Trefis Team $PFE $JNJ $RHHBY

  6. Roche s Cancer Segment Is Likely To Remain Strong In Near To Medium Term http://www.trefis.com/stock/rhhby/articles/292074/roches-cancer-segment-is-likely-to-remain-strong-in-near-to-medium-term/2015-04-30 by Trefis Team $RHHBY $BMY $MRK

  7. Roche Earnings Preview: Cancer Drug Growth Will Be Offset By Legacy Declines And A... http://www.trefis.com/stock/rhhby/articles/289541/roche-earnings-preview-cancer-drug-growth-will-be-offset-by-legacy-declines-and-adverse-currency-movement-apr-22/2015-04-21 by Trefis Team $RHHBY $JNJ $PFE

  8. Here Are The Prime Catalysts For Roche s Stock http://www.trefis.com/stock/rhhby/articles/288827/here-are-the-prime-catalysts-for-roches-stock/2015-04-10 by Trefis Team $RHHBY $BMY $MRK

  9. Three Biotechs that Could Radically Change the Practice of Medicine Forever: Wasatch Analyst Jill... http://www.trefis.com/stock/ino/articles/287127/three-biotechs-that-could-radically-change-the-practice-of-medicine-forever-wasatch-analyst-jill-wahleithner/2015-04-01 $INO $RHHBY $NVO

  10. What Does Recent Biosimilar Approval By The FDA Mean? http://www.trefis.com/stock/rhhby/articles/286282/what-does-recent-biosimilar-approval-by-the-fda-mean/2015-03-24 by Trefis Team $BMY $JNJ $MRK

  11. Pfizer Can Add 5%-10% Value By Streamlining Its R&D SPending http://www.trefis.com/stock/pfe/articles/285627/pfizer-can-add-5-10-value-by-streamlining-its-rd-spending/2015-03-19 by Trefis Team $PFE $BMY $RHHBY

  12. These High-Quality European Dividend Payers Could Benefit From A Rising Dollar http://www.trefis.com/stock/spy/articles/285610/these-high-quality-european-dividend-payers-could-benefit-from-a-rising-dollar/2015-03-19 $BUD $UL $RHHBY

  13. These Two Catalysts Can Move Merck s Stock Up http://www.trefis.com/stock/mrk/articles/284621/these-two-catalysts-can-move-mercks-stock-up/2015-03-12 by Trefis Team $MRK $BMY $RHHBY

  14. The Key Contributor Of Roche s Value Is Not In Danger Yet http://www.trefis.com/stock/rhhby/articles/284112/the-key-contributor-of-roches-value-is-not-in-danger-yet/2015-03-09 by Trefis Team $RHHBY $MRK $BMY

  15. Merck s Partnership With NGM Is A Bold Move http://www.trefis.com/stock/mrk/articles/282775/mercks-partnership-with-ngm-is-a-bold-move/2015-03-02 by Trefis Team $MRK $RHHBY $PFE

  16. We Are Not Surprised That J&J May Be Selling Cordis http://www.trefis.com/stock/jnj/articles/282127/we-are-not-surprised-that-jj-may-be-selling-cordis/2015-02-24 by Trefis Team $JNJ $BSX $RHHBY

  17. Merck Posts Disappointing Numbers As Experimental Hepatitis C Treatment Loses Breakt... http://www.trefis.com/stock/mrk/articles/279530/feb-6publish-todaymerck-posts-disappointing-numbers-as-experimental-hepatitis-c-treatment-loses-breakthrough-designation/2015-02-06 by Trefis Team $MRK $PFE $BMY

  18. Roche Posts Solid Numbers But All Eyes On What The Future Holds For The Company http://www.trefis.com/stock/rhhby/articles/278273/roche-posts-solid-numbers-but-all-eyes-on-what-the-future-holds-for-the-company/2015-02-02 by Trefis Team $RHHBY $PFE $MRK

  19. Merck Earnings Preview http://www.trefis.com/stock/mrk/articles/275625/merck-earnings-preview-earnings-on-4th-feb/2015-02-02 by Trefis Team $MRK $PFE $RHHBY

  20. Bristol-Myers Squibb Earnings: Currency Headwinds Take The Shine Off Encouraging New... http://www.trefis.com/stock/bmy/articles/277962/bristol-myers-squibb-earnings-currency-headwinds-take-the-shine-off-encouraging-new-drug-sales/2015-01-29 by Trefis Team $BMY $PFE $MRK

  21. Roche Earnings Preview: Oncology Drugs And Tamiflu Will Help The Revenue Growth http://www.trefis.com/stock/rhhby/articles/275728/roche-earnings-preview-oncology-drugs-and-tamiflu-will-help-the-revenue-growthearnings-on-28-jan/2015-01-26 by Trefis Team $RHHBY $JNJ $MRK

  22. Bristol-Myers Squibb Earnings Preview: Increasing Sales From New Drugs May Ease Th... http://www.trefis.com/stock/bmy/articles/275448/bristol-myers-squibb-earnings-preview-increasing-sales-from-new-drugs-may-ease-the-pressure-off-revenue-growth-earnings-on-27-jan/2015-01-23 by Trefis Team $BMY $MRK $RHHBY

  23. How Roche Will Perform In 2015? http://www.trefis.com/stock/rhhby/articles/273912/how-roche-will-perform-in-2015/2015-01-09 by Trefis Team $RHHBY $JNJ $PFE

  24. What 2015 Will Bring For Bristol-Myers Squibb http://www.trefis.com/stock/bmy/articles/273537/what-2015-will-bring-for-bristol-myers-squibb/2015-01-07 by Trefis Team $BMY $MRK $RHHBY

  25. The Year 2014 In Review: How Johnson & Johnson Became More Pharma Focused http://www.trefis.com/stock/jnj/articles/271038/the-year-2014-in-review-how-johnson-johnson-became-more-pharma-focused/2014-12-29 by Trefis Team $JNJ $RHHBY $PFE